Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial.

Efficacy outcomes The ITT analysis revealed that the death or need for IMV percentage by day 28 was 12.9% in the participants in the tocilizumab group and 32.3% in the participants in the SOC group, although the comparison did not reach statistical significance (p = 0.068) (Table 2 ).

also in 111,027 other papers

The survival analysis showed a trend toward a higher accrued survival in the tocilizumab group, mainly after 10 days of randomization, however this difference did not reach statistical significance (Fig. 2 ).

also in 53,322 other papers